Investigational New Drug
NeuroBo Pharmaceuticals, a subsidiary of Dong-A ST, announced on April 4 that it has filed a second phase U.S. Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to develop DA-1241 for the treatment of non-alcoholic steatohepatitis (NASH).
The clinical trial will determine the efficacy and safety of DA-1241 in a 16-week, multicenter, randomized, double-blind, placebo-controlled, parallel comparison study on 87 patients suffering from NASH. NeuroBo Pharmaceuticals plans to initiate the clinical trial of DA-1241 in the third quarter of this year and finish it in the second half of 2024.
NeuroBo Pharmaceuticals is a NASDAQ-listed company based in the city of Boston it the United States and is a global R&D base of Dong-A Socio Group. It is responsible for the global development and commercialization of DA-1241 and DA-1726.
DA-1726 being developed for the treatment of obesity and NASH is waiting for a global Phase 1 IND application. DA-1726 simultaneously acts on GLP-1 receptors and glucagon receptors to suppress appetite, promote insulin secretion, and increase peripheral basal metabolism, ultimately leading to weight loss. Nonclinical studies have confirmed its potential as a treatment for nonalcoholic fatty liver disease apart from its weight loss effects.